if Acadia is going to pull that card and upserp neuren commercially, they would have done so already in PWS as they have a PWS program in trials
if they try to run a faux ph1/2 in a new rare disease to disrupt NEU, they will have a tough time PR wise within the rare disease community. not a lawyer, and not sure if such a legal loophole exists, but imo, negligible risk it will be realised.
if Acadia is going to pull that card and upserp neuren...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.25 |
Change
0.430(2.17%) |
Mkt cap ! $2.585B | |||
| Open | High | Low | Value | Volume |
| $19.89 | $20.39 | $19.77 | $5.715M | 283.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 355 | $20.22 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.29 | 302 | 1 |
View Market Depth
| Last trade - 16.10pm 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$20.22 |
Change
0.430 ( 2.40 %) |
||||
| Open | High | Low | Volume | ||
| $19.86 | $20.40 | $19.77 | 85257 | ||
| Last updated 15.59pm 07/05/2024 ? | |||||
| NEU (ASX) Chart |